RE: SP24 Mar 2025 13:22
JFK - You are a dishonest ramper MorphoSys had many assets, including Monjunvi -
A commercialized therapy for diffuse large B-cell lymphoma (DLBCL), developed in collaboration with Incyte. In 2023, Monjuvi generated U.S. net product sales of $92 million, with projected sales between $80 million and $95 million for 2024.